MANUFACTURERS LIFE INSURANCE COMPANY, THE - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 141 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2016. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.

Quarter-by-quarter ownership
MANUFACTURERS LIFE INSURANCE COMPANY, THE ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$2,793,795
+16.5%
53,634
+41.6%
0.00%
+100.0%
Q2 2023$2,398,625
+19.9%
37,881
+2.6%
0.00%0.0%
Q1 2023$1,999,705
+2.7%
36,929
+0.4%
0.00%0.0%
Q4 2022$1,947,244
+16.1%
36,796
+2.1%
0.00%0.0%
Q3 2022$1,677,081
-19.8%
36,043
-1.7%
0.00%0.0%
Q2 2022$2,092,210
+4.7%
36,654
+12.2%
0.00%0.0%
Q1 2022$1,999,077
+11.0%
32,670
-5.1%
0.00%0.0%
Q4 2021$1,801,000
+38.6%
34,419
-1.2%
0.00%0.0%
Q3 2021$1,299,000
-16.9%
34,840
-9.1%
0.00%0.0%
Q2 2021$1,564,000
+28.1%
38,312
+6.5%
0.00%0.0%
Q1 2021$1,221,000
-0.1%
35,990
-6.4%
0.00%0.0%
Q4 2020$1,222,000
+31.8%
38,432
+6.4%
0.00%0.0%
Q3 2020$927,000
+16.3%
36,118
+14.1%
0.00%0.0%
Q2 2020$797,000
+65.4%
31,643
+0.9%
0.00%0.0%
Q1 2020$482,000
-46.3%
31,357
+19.9%
0.00%0.0%
Q4 2019$897,000
+333.3%
26,148
-5.3%
0.00%
Q3 2019$207,000
-42.2%
27,6180.0%0.00%
Q2 2019$358,000
+1.7%
27,618
-4.4%
0.00%
Q1 2019$352,000
+11.0%
28,892
+3.9%
0.00%
Q4 2018$317,000
-48.8%
27,810
-2.4%
0.00%
-100.0%
Q3 2018$619,000
+8.2%
28,500
-12.0%
0.00%0.0%
Q2 2018$572,000
-10.9%
32,386
+6.2%
0.00%0.0%
Q1 2018$642,000
+40.2%
30,498
-3.5%
0.00%
Q4 2017$458,000
+14.5%
31,620
+24.8%
0.00%
Q3 2017$400,000
+23.1%
25,346
-3.3%
0.00%
Q2 2017$325,000
-26.1%
26,204
-3.3%
0.00%
-100.0%
Q1 2017$440,000
+24.6%
27,085
+15.6%
0.00%0.0%
Q4 2016$353,000
+3.2%
23,433
+4.3%
0.00%0.0%
Q3 2016$342,000
-60.7%
22,472
+0.2%
0.00%0.0%
Q2 2016$870,000
+87.9%
22,417
+34.1%
0.00%
Q1 2016$463,000
-37.4%
16,716
+21.5%
0.00%
-100.0%
Q4 2015$740,000
+35.5%
13,758
+0.8%
0.00%0.0%
Q3 2015$546,000
+28.5%
13,654
+2.8%
0.00%0.0%
Q2 2015$425,000
+64.7%
13,288
+23.0%
0.00%
Q1 2015$258,000
+33.7%
10,799
-1.3%
0.00%
Q4 2014$193,000
+28.7%
10,9380.0%0.00%
Q3 2014$150,000
-17.6%
10,938
+1.6%
0.00%
Q2 2014$182,00010,7620.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2016
NameSharesValueWeighting ↓
Sarissa Capital Management LP 640,000$25,626,0006.33%
Redmile Group, LLC 1,322,592$52,957,0004.01%
SENZAR ASSET MANAGEMENT, LLC 556,224$22,271,209,0003.24%
RA Capital Management 314,349$12,587,0001.81%
WALL STREET ASSOCIATES 205,657$8,235,0001.58%
Parametrica Management Ltd 5,400$216,0001.36%
Rhenman & Partners Asset Management AB 165,000$6,607,0001.05%
EAM Investors, LLC 95,168$3,811,0000.60%
Rock Springs Capital Management LP 180,000$7,207,0000.58%
WASATCH ADVISORS LP 1,085,973$43,482,0000.58%
View complete list of INTRA CELLULAR THERAPIES INC shareholders